

**Supplementary Table 1.** Detailed information on the primer sequences

<b>Primers for real time PCR</b>	
UCA1-F	AAGAGATCCACCTGCGACCT
UCA1-R	CCTCCACCGTAAGAGTTACC
GAPDH-F	CATGGCCTTCCGTGTTCCCTA
GAPDH-R	TGTCATCATACTTGGCAGGTTT
U6-F	TGCTCGCTTCGGCAGCACAT
U6-R	CTTGCGCAGGGGCCATGCTA
MT RNR1-F	CCTCCCCAATAAAGCTAAAA
MT RNR1-R	GCTATTGTGTGTTTCAGATAT
$\beta$ -actin-F	AGTGTGACGTGGACATCCGCAAAG
$\beta$ -actin-R	ATCCACATCTGCTGGAAGGTGGAC
HGF-F	TAGGCACTGACTCCGAACA
HGF-R	AGGAGATGCAGGAGGACAT
c-MET-F	AGTGAGAAGGCTAAAGGAAACG
c-MET-R	TTTGGACCGTCAAGAAGTAAAT
<b>Primers for UCA1 cloning</b>	
UCA1-pLVX-F	CGGAATTCTGACATTCTTCTGGACAATGAGT
UCA1-pLVX-R	CGGGATCCCTGACTCTTTTAGGAAGATTCT
<b>Primers for construction luciferase reporter vectors</b>	
UCA1-pmirGLO-F	GCTCTAGATGACATTCTTCTGGACAATGAGT
UCA1-pmirGLO-R	TTTTCCTTTTGCGGCCCGCTGACTCTTTTAGGAAGATTCT
HGF-pmirGLO-F	GCTCTAGAACCTGAATGCCATGTGGGCCAT
HGF-pmirGLO-R	TTTTCCTTTTGCGGCCCGCTGATCATAGAAAAGTTTATTATTTTAAAAG
c-MET-pmirGLO-F	GCTCTAGATGCTAGTACTATGTCAAAGCAAC
c-MET-pmirGLO-R	TTTTCCTTTTGCGGCCCGCTTGCATCACTTTACTTTAATTGCAT

UCA1-pmirGLO-M-F	GTacaacaaGTTAGAGGGCTTGGGACATTTCACT
UCA1-pmirGLO-M-R	GCCCTCTAACttgtttgACATACTTTGTGTTGTCCTGGATGC
HGF-pmirGLO-M-F	CCTcaaacaaATTAACCAAATATTTTTAAAAATATTTTCCTC
HGF-pmirGLO-M-R	GGTTAATttgtttgAGGTAAGATATCTTAGTATAAACTTGGACAG
c-MET-pmirGLO-M-F	CCTTTTAAatacaacaaTGTTTTTTGAGACAGGATCTCACTCT
c-MET-pmirGLO-M-R	ttgtttgtaTTAAAAGGGAATGTTTACCTAATGGG

---

**Primers used for Sanger sequencing of KRAS, NRAS and BRAF**

---

KRAS-exon2-F (Codon G12, G13)	TCAAAGAATGGTCCTGCACC
KRAS-exon2-R (Codon G12, G13)	AGGCCTGCTGAAAATGACTG
KRAS-exon3-F (Codon Q61)	ATTATTTATGGCAAATACACAAAG
KRAS-exon3-R (Codon Q61)	TCTCCCTTCTCAGGATTC
KRAS-exon4-F (Codon A146)	GAGAGAAAACTGATATATTAATGAC
KRAS-exon4-R (Codon A146)	TTCTAGAACAGTAGACACAAAAC
KRAS-exon4-F (Codon K117)	CTGAGCCTGTTTTGTGTCTACTG
KRAS-exon4-R (Codon K117)	TTTTATGACAAAAGTTGTGGACAGG
NRAS-exon2-F (Codon G12, G13)	CCTCTATGGTGGGATCATATTC
NRAS-exon2-R (Codon G12, G13)	CTGATTACTGGTTTCCAACAG
NRAS-exon3-F (Codon Q61)	CCTTCGCCTGTCCTCATGTA
NRAS-exon3-R (Codon Q61)	TTGAACTTCCCTCCCTCCCT
NRAS-exon4-F (Codon A146)	AATATGAATATGGATCACATCTCTA
NRAS-exon4-R (Codon A146)	ATGGTGCTAGTGGGAAACAAGTGTG
NRAS-exon4-F (Codon K117)	TAACTCTTGGCCAGTTCGTGG
NRAS-exon4-R (Codon K117)	AGGGAGCAGATTAAGCGAGTA
BRAF-exon11-F (Codon G465, G468, Y472)	AAAAGTTGTAAACATATCCTATT
BRAF-exon11-R (Codon G465, G468, Y472)	GGGACTCGAGTGATGA
BRAF-exon15-F	GTA ACTCAGCAGCATCTCAGG

BRAF-exon15-R

GCTTGCTCTGATAGGAAAATGAG

---

**Supplementary Table 2.** Clinic-pathological characteristics of metastatic CRC patients with paired specimen pre- and post-cetuximab treatment

No.	Gender	Age	Primary site	Metastatic sites	Differentiation <sup>1</sup>	Cetuximab regimen <sup>2</sup>	Best response to cetuximab <sup>3</sup>	Site of specimen (pre)	Site of specimen (post)
1	M	55	rectosigmoid	liver	G2	FOLFOX4+cetuximab	PR	rectum	rectum
2	F	36	left colon	liver, lung, peritonealcavity	G1-G2	FOLFOX4+cetuximab	PR	sigmoid	liver lesion
3	M	67	left colon	liver, lung	G2	FOLFOX4+cetuximab	PR	sigmoid	sigmoid
4	M	59	left colon	left ovary and adnexa, lung	G1	FOLFIRI+cetuximab	SD	sigmoid	left adnexal mass
5	M	73	rectum	liver	G2	FOLFOX4+cetuximab	PR	rectum	liver lesion
6	M	80	transverse colon	liver, bone	G3	Cetuximab	SD	transverse colon	transverse colon
7	F	52	left colon	liver	G2-G3	FOLFIRI+cetuximab	SD	left colon	liver lesion
8	F	45	left colon	liver	G1	FOLFOX4+cetuximab	PR	sigmoid	liver lesion
9	M	42	right colon	liver, lung, peritoneal cavity	G2	FOLFIRI+cetuximab	SD	hepatic flexure of colon	abdominal wall mass
10	F	58	left colon	liver, lung, peritoneal cavity	G2	mFOLFOX6+cetuximab	SD	sigmoid	omental mass

1. G1, well-differentiated, G2, moderately differentiated, G3, poorly differentiated.

2. Cetuximab 400 mg/m<sup>2</sup> initial dose followed by 250 mg/m<sup>2</sup> weekly thereafter with cetuximab dose intensity >90% were given to all subjects.

Chemotherapy regimens: FOLFOX4 or mFOLFOX6, modified FOLFOX6 (5-fluorouracil, leucovorin, and oxaliplatin).

3. PR, partial response; SD, stable disease.

**Supplementary Table 3.** The antibodies used in the present study

<b>Name</b>	<b>Company</b>	<b>Code</b>
p-MET	Santa Cruz	sc-101736
MET	Santa Cruz	sc-514148
p-p85	CST	4228
p85	CST	4292
p-AKT (Ser <sup>473</sup> )	CST	4060
AKT	CST	4691
p-p44/42 MAPK (Thr <sup>202</sup> , Tyr <sup>204</sup> )	CST	4370
p44/42 MAPK	CST	4695
$\beta$ -actin	Santa Cruz	sc-47778
TR Monoclonal Antibody	Proteintech	67728-1-Ig
Goat Anti-Rabbit IgG-FITC	Proteintech	SA00003-2